Compare Mesoblast Limited (MESO) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Mesoblast Limited trades at $16.76 (market cap $2.21B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $11.38. The key difference: Mesoblast Limited is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| MESO | MSTZ | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $20.96 | $27.92 |
52-Week Low | $12.88 | $3.88 |
Enterprise Value | $2.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
MSTZ trades at $11.27, up 4.16% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Financial ratios are unavailable, limiting fundamental assessment. Recent news highlights ETF performance unrelated to MSTZ, with no direct company updates provided.
The outlook is cautious due to bearish technicals and lack of fundamental data. Risks include market volatility and unverified financial health. Investment opportunity hinges on future earnings clarity and positive analyst coverage, which are currently absent.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
